Meeting
2023 ASCO Annual Meeting
A phase (Ph) I/II trial of abiraterone acetate in combination with tildrakizumab (anti-IL23 monoclonal antibody) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Christina Guo
Institute of Cancer Research, London, United Kingdom
Christina Guo , Simon J. Crabb , Simon Pacey , Vicky Coyle , Sarah Danson , Guillermo Villacampa , Khobe Chandran , Alec Paschalis , Ruth Riisnaes , Ana Ferreira , Suzanne Carreira , Claudia Bertan , Mateus Crespo , Ines Figueiredo , Ruth Matthews , Alison Joanne Turner , Christina Yap , Andrea Alimonti , Adam Sharp , Johann S. De Bono
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT04458311
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5105)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5105
Abstract #
TPS5105
Poster Bd #
195b
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Guo Hongqian
Poster
2020 Genitourinary Cancers Symposium
A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Wassim Abida
Poster
2019 Genitourinary Cancers Symposium
Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Jingsong Zhang
Poster
2024 ASCO Genitourinary Cancers Symposium
Somatostatin receptor 1 (SSTR1) expression as a potential predictive biomarker for response to androgen receptor signaling inhibitor (ARSI) therapy in metastatic castration-resistant prostate cancer (mCRPC).
First Author: Xiaolin Zhu